MRVT starts Phase II psoriasis study

Miravant Medical (MRVT) began a U.S. open-label, dose-ranging Phase II trial of its PhotoPoint photodynamic therapy (PDT) in 54 patients with moderate plaque psoriasis. Patients will receive varying d...